Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study - 14/03/18
, Nicole Williams, BS j, Adriana Guana, MD h, Mark G. Lebwohl, MD kAbstract |
Background |
Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile.
Objective |
To assess the impact of secukinumab versus that of ustekinumab on complete relief from psoriasis-related symptoms, time to response in terms of health-related quality of life, and cumulative benefit among patients with moderate-to-severe plaque psoriasis.
Methods |
Psoriasis-related pain, itching, and scaling and the Dermatology Life Quality Index (DLQI) score were compared between treatments on the basis of time to complete relief of symptoms and time to DLQI response in the CLEAR trial. Cumulative benefit over 52 weeks based on Psoriasis Area and Severity Index score, symptom relief, and DLQI response were evaluated by area under the curve analysis.
Results |
Significantly more patients treated with secukinumab achieved complete relief of pain at weeks 16 and 52 (all P < .05). Complete relief of itching and scaling occurred significantly faster with secukinumab (median, 4 weeks faster for itching and 8 weeks faster for scaling [P < .001]). Response as measured by the DLQI was 4 weeks faster with secukinumab (P < .0001). Cumulative benefits were greater with secukinumab (all P < .05).
Limitations |
Analyses were post hoc.
Conclusion |
This patient-reported outcome analysis confirms greater and sustained benefits of secukinumab versus those of ustekinumab treatment on patients' lives.
Le texte complet de cet article est disponible en PDF.Key words : cumulative benefit, itching, pain, psoriasis, quality of life, scaling, secukinumab
Abbreviations used : AUC, CI, DLQI, HRQoL, MCID, PASI, PRO
Plan
| Supported by Novartis Pharmaceuticals Corporation (East Hanover, NJ). |
|
| Disclosure: Dr Puig is a clinical study investigator for AbbVie, Amgen, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Regeneron, and Roche; he also has served as a consultant and/or speaker for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, LEO Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, and Sandoz. Dr Augustin has served as a consultant or paid speaker for clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Janssen-Cilag, Leo, Medac, Merck, MSD, Novartis, Pfizer, UCB, and XenoPort. Dr Blauvelt is a scientific advisor, clinical study investigator, and/or speaker for AbbVie, Aclaris, Allergan, Amgen, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lily and Company, Genentech/Roche, GlaxoSmithKline, Janssen, Leo, Merck Sharp & Dohme, Novartis, Pfizer, Purdue Pharma, Regeneron, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB, Valeant, and Vidac. Dr Gottlieb has current consulting or advisory board agreements with Amgen, Astellas, Akros, Centocor (Janssen), Celgene, Bristol Myers Squibb, Beiersdorf, Abbott Labs (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd, Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, Glaxo Smith Kline, Xenoport, Catabasis, Meiji Seika Pharma Co, Takeda, Mitsubishi, Tanabe Pharma Development America, Genentech, Baxalta, Kineta One, KPI Therapeutics, Crescendo Bioscience, Aclaris, Amicus, Reddy Labs, Valeant, Dermira, and Allergan and has received research/educational grants from Janssen and Incyte. Dr Vender has been a speaker for AbbVie, Amgen, Celgene, Galderma, Janssen, LEO Pharma, Novartis, and Pfizer and an investigator for AbbVie, Amgen, Celgene, Galderma, Janssen, LEO Pharma, Lilly, Merck, Novartis, and Pfizer. Dr Korman has been a consultant and advisor and/or received speaking fees and/or grants and/or served as an investigator in clinical trials for the following companies: Abbott/AbbVie, Amgen, Biogen Idec, Celgene, Chugai, Dermira, Eli Lilly, Immune Tolerance Network, Janssen, Kyowa Hakko Kirin, LEO Pharma, National Psoriasis Foundation, Merck, Novartis, Pfizer, Regeneron, and Trevi Pharmaceuticals. Dr Thaçi has been a consultant and advisor and/or received speaking fees and/or grants and/or served as an investigator in clinical trials for the following companies: AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, BMS, Celgene, Dignity, Eli Lilly, Forward Pharma, Galapagos, GSK, Leo, Janssen-Cilag, Maruho, Mitsubishi Pharma, MSD, Mundipharma, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi, and Xenoport. Dr Zhao was a full-time employee of Novartis Pharmaceuticals Corporation at the time of this research. Ms Gilloteau is a full-time employee of Novartis Pharma AG. Ms Sherif and Ms Williams are full-time employees of RTI Health Solutions. Dr Guana is a full-time employee of Novartis Pharmaceuticals Corporation. Dr Lebwohl is an employee of the Mount Sinai Medical Center, which receives research funds from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, Medimmune/Astra Zeneca, Novartis, Pfizer, and Vidac. |
|
| Reprints not available from the authors. |
Vol 78 - N° 4
P. 741-748 - avril 2018 Retour au numéro
Article précédent
- A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis
- Sherry H. Yu, Aaron M. Drucker, Mark Lebwohl, Jonathan I. Silverberg
- Estimating the health care costs associated with recurrent cellulitis managed in the outpatient setting
- Jessica St. John, Lauren Strazzula, Priyanka Vedak, Daniela Kroshinsky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?